News
-
-
-
PRESS RELEASE
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy -
-
-
-
-
-
-